X-Neu5Ac|CAS 160369-85-7|DC Chemicals

Cas No.:	160369-85-7
Chemical Name:	5-Bromo-4-chloro-3-indolyl-a-D-N-acetylneuraminic Acid, Sodium Salt
Synonyms:	5-Bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid sodium salt;5-Bromo-4-chloro-3-indolyl α-D-N-acetylneuraminic acid sodium salt (X-NeuNAc);5-Bromo-4-chloro-3-indolyl α-D-N-acetylneuraminic acid sodium salt;5-BROMO-4-CHLORO-3-INDOLYL-A-D-N-ACETYLNEURAMINIC ACID, SODIUM SALT;5-Bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid(sodium salt);5-Bromo-4-chloro-3-indolyl-α-D-N-acetylneuraminic Acid, Sodium Salt;X-NeuNAc;5-BroMo-4-chloro-3-indolyl a-d-n(-20`C);X-Neu5Ac;X-NANA.Na;5-bromo-4-chloro-3-indolyl α-D-N-acetylneuramini;5-bromo-4-chloro-3-indolyl A-D-N-acetylneuramini;5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid;5-Bromo-4-chloro-3-indolyl-a-D-N-acetylneuraminic Acid, Na;5-Bromo-4-chloro-3-indolyl-α-D-N-acetylneuraminic Acid, Sodium Sal
SMILES:	O=C([C@@]1(OC2=CNC3=C2C(Cl)=C(Br)C=C3)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1)[O-].[Na+]
Formula:	C₁₉H₂₁N₂O₉ClBr-^.Na+
M.Wt:	559.72484
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
DC74641	HC-258	HC-258 is a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration. HC-258 reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells. Co-crystallization with hTEAD2 confirmed that HC-258 binds within TEAD’s PA pocket, where it forms a covalent bond with its cysteine.
DC74639	Oligopeptide-10	Oligopeptide-10, also known as granactive oligopeptide-10, is a synthetic bio-active peptide composed of 15 amino acids. it can help manage acne-causing bacteria, both on its own and in conjunction with anti-acne superstar exfoliant salicylic acid.
DC74638	GLPG3667	GLPG3667 is an oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor. It is being developed to treat inflammatory and auto-immune diseases. Biochemical assays showed that GLPG3667 displayed nanomolar potency on TYK2 with a selectivity over other JAK kinases >3-fold. In human PBMC, GLPG3667 showed comparable potency on the IFNα and IL-23 pathways (around 50 nM). Selectivity for TYK2 on the IFNα pathway was >14-fold and >19-fold toward the IL-2 and GM-CSF pathways in human PBMC and whole blood, respectively. Dermal ear inflammation in a mouse model of psoriasis driven by IL-23 was prevented by GLPG3667 with a minimal effective dose of 3 mg/kg given orally once daily. This effect was associated with a decrease in neutrophil infiltration and STAT3 phosphorylation at sites of inflammation. In healthy HV, GLPG3667 completely inhibited IFNα-induced STAT1 and STAT3 phosphorylation but did not impact IL-2- and GM-CSF-induced STAT5 phosphorylation.